Search Results - "Gray, OM"

  • Showing 1 - 9 results of 9
Refine Results
  1. 1

    A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis by STEIN, M. S, LIU, Y, KILPATRICK, T. J, GRAY, O. M, BAKER, J. E, KOLBE, S. C, DITCHFIELD, M. R, EGAN, G. F, MITCHELL, P. J, HARRISON, L. C, BUTZKUEVEN, H

    Published in Neurology (25-10-2011)
    “…Higher latitude, lower ultraviolet exposure, and lower serum 25-hydroxyvitamin D (25OHD) correlate with higher multiple sclerosis (MS) prevalence, relapse…”
    Get full text
    Journal Article
  2. 2

    Tried and tested: the psychometric properties of the multiple sclerosis impact scale (MSIS-29) in a population-based study by Gray, OM, McDonnell, GV, Hawkins, SA

    Published in Multiple sclerosis (01-01-2009)
    “…Objective To investigate the psychometric properties of the Multiple Sclerosis Impact Scale (MSIS-29) and to assess the relationship between the Kurtzke…”
    Get full text
    Journal Article
  3. 3

    PREDICTORS OF POSTPARTUM RELAPSES IN WOMEN WITH MULTIPLE SCLEROSIS: RESULTS FROM THE MSBASE REGISTRY by Hughes, SE, Spelman, T, Gray, OM, Boz, C, Trojano, M, McDonnell, GV, Hawkins, SA, Kee, F, Butzkueven, H

    “…Background Several studies have shown that pregnancy reduces relapse rate in Multiple Sclerosis (MS), followed by an increased relapse rate in the early…”
    Get full text
    Journal Article
  4. 4

    Factors in the rising prevalence of multiple sclerosis in the north-east of Ireland by Gray, OM, McDonnell, GV, Hawkins, SA

    Published in Multiple sclerosis (01-08-2008)
    “…Background Northern Ireland is recognized as an area of high risk for multiple sclerosis. The original study of Allison and Millar in 1951 found a prevalence…”
    Get full text
    Journal Article
  5. 5

    Time to regression from trial-defined disease progression in multiple sclerosis is dependent upon baseline Expanded Disability Status Scale by Gray, OM, Butzkueven, H, Jolley, D, Hoffmann, M W

    Published in Multiple sclerosis (01-09-2008)
    “…Background: Trials in multiple sclerosis (MS) utilize a one-point progression of the Kurtzke Expanded Disability Status Scale (EDSS) sustained at 3 months as a…”
    Get full text
    Journal Article
  6. 6

    A systematic review of oral methotrexate for multiple sclerosis by Gray, O M, McDonnell, G V, Forbes, R B

    Published in Multiple sclerosis (01-08-2006)
    “…Oral methotrexate is a potent immunosuppressant, which could have a beneficial effect on relapse rates and delay disease progression in multiple sclerosis…”
    Get full text
    Journal Article
  7. 7

    An investigation of susceptibility loci in benign, aggressive and primary progressive multiple sclerosis in Northern Irish population by Gray, OM, Abdeen, H, McDonnell, GV, Patterson, CC, Graham, CA, Hawkins, SA

    Published in Multiple sclerosis (01-03-2009)
    “…Objective To investigate the possibility that susceptibility loci in multiple sclerosis (MS) have a role in determining the disease outcome in Northern Ireland…”
    Get full text
    Journal Article
  8. 8
  9. 9

    Primary isolated brainstem injury producing internuclear ophthalmoplegia by Gray, O. M., Forbes, R. B., Morrow, J. I.

    Published in British journal of neurosurgery (01-10-2001)
    “…Brainstem injuries are classically associated with a grave prognosis. We present a case of a male with primary isolated brainstem injury who had a right…”
    Get full text
    Journal Article